KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted): 2015-2024

Historic EPS (Weighted Average and Diluted) for Halozyme Therapeutics (HALO) over the last 10 years, with Dec 2024 value amounting to $3.43.

  • Halozyme Therapeutics' EPS (Weighted Average and Diluted) rose 36.19% to $1.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.75, marking a year-over-year increase of 57.28%. This contributed to the annual value of $3.43 for FY2024, which is 63.33% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' EPS (Weighted Average and Diluted) is $3.43, which was up 63.33% from $2.10 recorded in FY2023.
  • Halozyme Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $3.43 during FY2024, with a 5-year trough of $0.91 in FY2020.
  • In the last 3 years, Halozyme Therapeutics' EPS (Weighted Average and Diluted) had a median value of $2.10 in 2023 and averaged $2.32.
  • As far as peak fluctuations go, Halozyme Therapeutics' EPS (Weighted Average and Diluted) soared by 282.00% in 2020, and later crashed by 47.45% in 2022.
  • Halozyme Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at $0.91 in 2020, then soared by 201.10% to $2.74 in 2021, then tumbled by 47.45% to $1.44 in 2022, then spiked by 45.83% to $2.10 in 2023, then soared by 63.33% to $3.43 in 2024.